New York, NY—December 22, 2004
The latest news about a National Cancer Institute study finding an increased risk of heart attacks among patients taking Celebrex®, which follows Merck's voluntary withdrawal of Vioxx®, is causing concern among patients afflicted by a variety of orthopedic and rheumatic conditions who take Cox-2 inhibitors. Another study released on Dec. 20 suggested possible heart attack risk from Aleve®. Whether patients are recovering from joint replacement surgery or sports injuries, or suffering from arthritis, osteoarthritis or lupus, they are looking to their healthcare practitioners to help them put this data into perspective and help them make the right treatment decisions.
The following Hospital for Special Surgery doctors are available to comment on COX-2 inhibitors and non-steroidal anti-inflammatory agents and how recent data can be put into context for patients:
Theodore R. Fields, MD, FACP
Associate Attending Physician
Available to discuss: Medication alternatives to COX-2 inhibitors, non-medication approaches to arthritis, the COX-2 selective vs non-selective anti-inflammatory agents
Joseph A. Markenson, MD
Available to discuss: Current drug studies involving patients with rheumatic disease (rheumatoid arthritis, osteoarthritis, and lupus), medication alternatives to COX-2s, reasons for withdrawal of Vioxx®, non-medication approaches to arthritis, the COX-2 selective vs non-selective anti-inflammatory agents
Thomas J.A. Lehman, MD
Chief, Division of Pediatric Rheumatology
Available to discuss: Implications for children with Juvenile Rheumatoid Arthritis
Lehman, author of It's Not Just Growing Pains, published by Oxford University Press, devotes a section of the book to the various medications available to children with rheumatic diseases and the reasons for taking medications even if they pose potential risks to children.
Scott A. Rodeo, MD
Clinician-scientist, Department of Orthopedic Surgery (Sports Medicine and Shoulder Service) and the Research Department (Laboratory for Soft Tissue Research) and Associate team physician for New York Giants
Available to discuss: Implications for athletes and sports injuries
Michael D. Lockshin, MD
Director, Barbara Volcker Center for Women and Rheumatic Disease
Available to discuss: Alternatives for patients suffering from rheumatic diseases
Seth A. Waldman, MD
Assistant Attending Anesthesiologist
Director, Division of Pain Medicine
Available to discuss: The use of NSAIDs in a comprehensive pain medication regimen, and how this has changed with the new recalls
About HSS | Hospital for Special Surgery
HSS is the world’s leading academic medical center focused on musculoskeletal health. At its core is Hospital for Special Surgery, nationally ranked No. 1 in orthopedics (for the eighth consecutive year) and No. 3 in rheumatology by U.S. News & World Report (2017-2018). Founded in 1863, the Hospital has one of the lowest infection rates in the country and was the first in New York State to receive Magnet Recognition for Excellence in Nursing Service from the American Nurses Credentialing Center four consecutive times. The global standard total knee replacement was developed at HSS in 1969. An affiliate of Weill Cornell Medical College, HSS has a main campus in New York City and facilities in New Jersey, Connecticut and in the Long Island and Westchester County regions of New York State. In 2017 HSS provided care to 135,000 patients and performed more than 32,000 surgical procedures. People from all 50 U.S. states and 80 countries travelled to receive care at HSS. In addition to patient care, HSS leads the field in research, innovation and education. The HSS Research Institute comprises 20 laboratories and 300 staff members focused on leading the advancement of musculoskeletal health through prevention of degeneration, tissue repair and tissue regeneration. The HSS Global Innovation Institute was formed in 2016 to realize the potential of new drugs, therapeutics and devices. The culture of innovation is accelerating at HSS as 130 new idea submissions were made to the Global Innovation Institute in 2017 (almost 3x the submissions in 2015). The HSS Education Institute is the world’s leading provider of education on the topic on musculoskeletal health, with its online learning platform offering more than 600 courses to more than 21,000 medical professional members worldwide. Through HSS Global Ventures, the institution is collaborating with medical centers and other organizations to advance the quality and value of musculoskeletal care and to make world-class HSS care more widely accessible nationally and internationally.